2011-05-13T12:12:21-05:00 2010-06-30 AKT LLP 312 S Juniper Street Suite 100 Escondido CA 92025 990 2009-07-01 330903864 VACCINE RESEARCH INSTITUTE OF SAN DIEGO VACC 8585813960 10835 ROAD TO THE CURE No 150 SAN DIEGO CA 92121 DAVID MILICH 8585813960 2011-05-11 1 Elsa A Romero 7607461560 2011-05-11 2009 2016-02-24 21:20:13Z David R Milich 10835 ROAD TO THE CURE No 150 SAN DIEGO CA 92121 2954199 0 X www.vrisd.org X 2000 CA development of products to treat and/or prevent viral infections & certain other infectious diseases. 3 2 26 0 0 0 1514979 2925657 0 3 1042 24000 27500 1538982 2954199 95014 337409 0 735940 1430397 0 0 733794 1240465 1564748 3008271 -25766 -54072 232217 521944 223293 567092 8924 -45148 Our mission is scientific research focusing on development of preventative and therapeutic treatments for both infectious (malaria, hepatitis B and C, and influenza) and non-infectious diseases (cancer and cardiovascular disease). 1 0 1902541 337408 Chronic Hepatitis B Infection and Therapeutic Vaccines.Progress on characterization of a unique HBeAg-specific, DN (double negative) Treg cell population. Clinical studies have recently implicated regulatory T cells (Tregs) in HBV persistence. Our studies in HBc/HBeAg x TCR-double-Tg mice have also identified a novel Treg cell induced by the secretory HBeAg, but not by the HBcAg.Significant progress on a CTL-mediated liver injury model using gene array and qRT-PCR methods. To explain the emergence of HBeAg-negative mutants during chronic infection, we have developed a model of liver injury and unexpectedly the same CTLs transferred into HBeAg-Tg and HBcAg-Tg mice elicited a more severe liver injury of a longer duration in the HBeAg-Tg recipients suggesting that the HBeAg-negative mutant may represent a CTL escape mutation.Continue development of a therapeutic vaccine for chronic HBV infection using WHcAg hybrid VLPs. Our innovative approach is to use the WHcAg species variant as a vaccine platform to deliver neutralizing HBV-PreS B cell epitopes. We have already demonstrated that WHcAg-PreS VLPs circumvent HBV-specific T cell tolerance. 459985 459985 Malaria - Hybrid-WHcAg VLPs carrying 2 CS-repeat B cell epitopes and 4 CS-nonrepeat B cell epitopes were produced, purified and used to immunize mice. All constructs elicited high levels of anti-insert antibodies.The hybrid-WHcAg VLPs carrying CS-repeat B cell epitopes conferred 98.7% protection against a 10,000 hybrid sporozoite challenge, whereas the non-repeat B cell epitopes were minimally to non-protective. Although anti-CS non-repeat antibodies bound dry sporozoites, viable sporozoites were not recognized by anti-CS non-repeat antibodies. The cryptic nature of CS-nonrepeat epitomes on viable sporozoites may explain the lack of protection. Comparing CS-repeat B cell epitopes, anti-NANP antibodies were more protective than anti-NVDP antibodies.Human CD4+ / CD8+ T cell recognition sites were also inserted onto hybrid-WHcAg VLPs (i.e. UTC, TH.3R, CS.T3) and a VLP construct containing all 3 well characterized T cell domains primed murine CS-specific T cells as well as WHcAg-specific T cells.Transgenic P.berghei parasites expressing the P. falciparium C terminus, which contains the majority of human T cell recognition sites, were produced. The new hybrid P.berghei/P.falciparium parasites are fully viable and infect mosquitoes and mice normally. 360198 360198 Salmonella Genes associated with Colonization of Specific Hosts.This project has generated a resource of mutants in almost every protein coding gene in the pathogen Salmonella. This resource is being used in research laboratories worldwide to understand how this organism infects humans and domestic animals. Beyond the scope of this project, the resource is now also being used to improve Salmonella as a vector for vaccines and for delivering cancer therapeutics. 2722724 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 2 0 26 1 0 0 0 0 0 0 0 0 0 3 2 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 CA X RICHARD E BRANDT 8585813960 10835 Road to the Cure Suite 150 SAN DIEGO CA 92121 David R Milich PhD 40.00 X X 138801 0 32797 JANICE HUGHES 40.00 X X 89534 0 27122 michael mcclelland 40.00 X X 82866 0 10410 richard brandt 40.00 X X 0 0 0 TERRY DILLMAN 1.00 X 0 0 0 RANDY HORTON 1.00 X 0 0 0 311201 0 70329 1 0 1 0 0 2766881 158776 2925657 1042 1042 27500 27500 27500 27500 2954199 0 0 28542 337409 337409 230386 159028 71358 925578 919042 6536 178284 168519 9765 96149 90883 5266 16686 16686 108372 86698 21674 602 602 689128 551985 137143 1853 1853 2411 1696 715 2020 2020 7756 7756 22574 4515 18059 SUPPLIES 191450 182510 8940 ANIMAL COSTS 162332 162125 207 equipment repair and ma 24668 24024 644 telephone 14762 11810 2952 miscellaneous 13256 6326 6930 -17405 13699 -31104 3008271 2722724 285547 0 14853 67658 102079 286647 0 67583 95247 91036 196505 188155 7156 8350 12882 670 232217 521944 112754 154510 100000 74815 10539 0 337767 223293 567092 X 8924 -45148 8924 -45148 232217 521944 X 0 1 1 X 1 1 X 1931380 1682734 1511045 1514979 2925657 9565795 1931380 1682734 1511045 1514979 2925657 9565795 30399 9535396 152 309 11261 24003 28542 64267 9630062 0.99020 0.98120 X 196505 188155 8350 8350 unearned revenue 264584 deferred rent 73183 337767 2954199 3008271 -54072 0 -54072 2954199 0 2954199 0 2954199 3008271 0 3008271 0 3008271 1 Virginia Commonwealth University stranger hall box 614 richmond VA 23298 520595110 501(c)(3) 65413 research grants john hopkins university 615 n wolfe st stee3630 baltimore MD 21205 546001758 501(c)(3) 153989 research grants texas a&m research foundation 400 harvey mitchell pkwy college station TX 77845 741238434 501(c)(3) 50970 research grants the ohio state university 1960 kenny road columbus OH 43210 316401599 501(c)(3) 67037 research grants 4 X 0 0 0 0 0 0 0 0 0 David R Milich PhD 138801 0 0 0 0 0 6072 0 26725 0 171598 0 181779 0 Michael McClelland PhD fund research projects X 100000 74815 0 1 1 74815 Form 990, Part III, line 2 New Program Services VRISD has expanded through the addition of a team of scientists from the Sidney Kimmel Cancer Center. Joining the Institute are Dr. Michael McClelland as Full Member and the new Scientific Director; Dr. Per Borgstrom and Dr. John Welsh as Associate Members; and Dr. Veronique Baron as Assistant Member. These distinguished scientists bring to the VRISD targeted cancer research and research on Salmonella. They have been funded though the National Institute of Health, the Department of Defense, and the State of California (California Breast Research Program). Other scientists that have joined VRISD as a part of their team are Dr. Parisa Abedinpour, Dr. Rocio Canals, Dr. Steffen Porwollik, Dr. Gaelle Rondeau, Dr. Yipeng Wang, and Dr. Xiao-Qin Xia. Form 990, Part VI, Section B, line 11 tHE CEO REVIEWS THE 990 PRIOR TO FILING Form 990, Part VI, Section B, line 12c All board members must fill out an annual statement on any possible conflict of interest. Form 990, Part VI, Section B, line 15 Salaries not to exceed new hire cap of $197,700. Salary increases are voted on by the board of directors. Form 990, Part VI, Section C, line 19 The organizational documents of the organization will be available (for inspection or copying) at the organization's main office during normal business hours. The public inspection copy of the organization's Form 990, from the previous three years, will be available (for inspection or copying) at the organization's main office during normal business hours. The audited financial statements will be available (for inspection or copying) at the organization's main office during normal business hours. When responding to a public inspection request for any organizational document or Form 990 by anyone, the organization shall fulfill such request in a timely fashion without inquiring as to the reason for the public inspection request. PART XI, LINE 2C THERE HAVE BEEN NO CHANGES FROM THE PREVIOUS YEAR. VLP Biotech Inc 10835 Road to the Cure Sutie 150 SAN DIEGO CA 92121 200425548 Biotechnology CA N/A C 1 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0